BeOne Medicines
ONC
#780
Rank
NZ$53.18 B
Marketcap
NZ$512.58
Share price
-3.77%
Change (1 day)
34.49%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeOne Medicines (ONC)

Earnings in 2026 (TTM): NZ$1.30 Billion

According to BeOne Medicines's latest financial reports the company's current earnings are NZ$5.73 Billion. In 2025 the company made an earning of NZ$0.82 Billion, an increase over its 2024 earnings that were of -NZ$0.96 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeOne Medicines from 2015 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$1.30 B57.17%
2025 NZ$0.82 B-186.57%
2024 -NZ$0.96 Billion-52.95%
2023 -NZ$2.04 Billion-32.52%
2022 -NZ$3.02 Billion24.39%
2021 -NZ$2.43 Billion-13.21%
2020 -NZ$2.79 Billion72.69%
2019 -NZ$1.62 Billion36.01%
2018 -NZ$1.19 Billion616.83%
2017 -NZ$0.17 Billion-15.24%
2016 -NZ$0.2 Billion107.91%
2015 -NZ$94.02 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
OPKO Health
OPK
-NZ$0.27 Billion-121.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
-NZ$30.56 Million-102.40%๐Ÿ‡บ๐Ÿ‡ธ USA